p21 regulates expression of ECM components and promotes pulmonary fibrosis via CDK4 and Rb.
Abstract
Fibrosis and accumulation of senescent cells are common tissue changes associated with aging. Here, we show that the CDK inhibitor p21 (CDKN1A), known to regulate the cell cycle and the viability of senescent cells, also controls the expression of extracellular matrix (ECM) components in senescent and proliferating cells of the fibrotic lung, in a manner dependent on CDK4 and Rb phosphorylation. p21 knockout protects mice from the induction of lung fibrosis. Moreover, inducible p21 silencing during fibrosis development alleviates disease pathology, decreasing the inflammatory response and ECM accumulation in the lung, and reducing the amount of senescent cells. Furthermore, p21 silencing limits fibrosis progression even when introduced during disease development. These findings show that one common mechanism regulates both cell cycle progression and expression of ECM components, and suggest that targeting p21 might be a new approach for treating age-related fibrotic pathologies.
The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.
Research summary
The paper addresses the role of p21 in regulating ECM components and its implications for pulmonary fibrosis, linking it to the accumulation of senescent cells, which is a significant aspect of aging. By suggesting that targeting p21 could be a new approach for treating age-related fibrotic pathologies, it touches on potential interventions that could mitigate age-related changes. However, while the findings are important, they represent a solid contribution rather than a groundbreaking advance in the field of longevity research.
Author of this paper? Send a correction.